• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis.

作者信息

Schrier R W, Gurevich A K, Cadnapaphornchai M A

机构信息

Department of Medicine, University of Colorado Health Sciences Center, Denver, CO, USA.

出版信息

Semin Nephrol. 2001 Mar;21(2):157-72. doi: 10.1053/snep.2001.20933.

DOI:10.1053/snep.2001.20933
PMID:11245778
Abstract

The kidneys play the crucial role in the maintenance of the body fluid volume homeostasis. Several hypotheses have been introduced to explain sodium and water retention leading to edematous states in such pathologic conditions as congestive heart failure (CHF) and cirrhosis. We have suggested a unifying arterial underfilling hypothesis, explaining the development of edema in these conditions. Arterial underfilling, caused by decreased cardiac output or peripheral arterial vasodilation, leads to activation of the sympathetic nervous system, renin-angiotensin-aldosterone system, and nonosmotic vasopressin release. This review discusses the pathophysiologic mechanisms resulting in renal sodium and water retention, impaired mineralocorticoid escape, and resistance to atrial natriuretic peptide in patients with CHF and cirrhosis. Furthermore, the basis of current therapies in these disorders is discussed, including beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, aldosterone antagonists, and diuretics in CHF and cirrhosis, as well as new approaches to treatment of water retention with vasopressin V(2) receptor antagonists.

摘要

相似文献

1
Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis.
Semin Nephrol. 2001 Mar;21(2):157-72. doi: 10.1053/snep.2001.20933.
2
Water and sodium retention in edematous disorders: role of vasopressin and aldosterone.水肿性疾病中的水钠潴留:血管加压素和醛固酮的作用
Am J Med. 2006 Jul;119(7 Suppl 1):S47-53. doi: 10.1016/j.amjmed.2006.05.007.
3
Sodium and water retention in heart failure: pathogenesis and treatment.
Kidney Int Suppl. 1997 Jun;59:S57-61.
4
Pathophysiology of vasopressin in edematous disorders.血管加压素在水肿性疾病中的病理生理学
Nihon Naibunpi Gakkai Zasshi. 1989 Dec 20;65(12):1311-27. doi: 10.1507/endocrine1927.65.12_1311.
5
Unifying hypothesis of sodium and water regulation in health and disease.
Hypertension. 1991 Nov;18(5 Suppl):III164-8. doi: 10.1161/01.hyp.18.5_suppl.iii164.
6
Use of diuretics in heart failure and cirrhosis.利尿剂在心衰和肝硬化中的应用。
Semin Nephrol. 2011 Nov;31(6):503-12. doi: 10.1016/j.semnephrol.2011.09.005.
7
A unifying hypothesis of sodium and water regulation in health and disease.健康与疾病状态下钠和水调节的统一假说。
Horm Res. 1990;34(3-4):118-23. doi: 10.1159/000181809.
8
Pathogenesis of water and sodium retention in cirrhosis.肝硬化中钠水潴留的发病机制。
Kidney Int Suppl. 1997 Jun;59:S43-9.
9
Edematous disorders: pathophysiology of renal sodium and water retention and treatment with diuretics.水肿性疾病:肾钠水潴留的病理生理学及利尿剂治疗
Curr Opin Nephrol Hypertens. 1993 Sep;2(5):798-805.
10
Pathogenesis of sodium and water retention in edematous disorders.水肿性疾病中钠水潴留的发病机制。
Am J Kidney Dis. 1982 Sep;2(2):241-54. doi: 10.1016/s0272-6386(82)80070-x.

引用本文的文献

1
Pattern Clustering of Symmetric Regional Cerebral Edema on Brain MRI in Patients with Hepatic Encephalopathy.肝性脑病患者脑MRI上对称区域脑水肿的模式聚类
J Korean Soc Radiol. 2024 Mar;85(2):381-393. doi: 10.3348/jksr.2023.0012. Epub 2024 Mar 26.
2
Effects of Angiotensin 1-7 and Mas Receptor Agonist on Renal System in a Rat Model of Heart Failure.血管紧张素 1-7 和 Mas 受体激动剂对心力衰竭大鼠肾脏系统的影响。
Int J Mol Sci. 2023 Jul 14;24(14):11470. doi: 10.3390/ijms241411470.
3
Improving Diuretic Response in Heart Failure by Implementing a Patient-Tailored Variability and Chronotherapy-Guided Algorithm.
通过实施患者个体化的变异性和时间疗法指导算法改善心力衰竭患者的利尿反应
Front Cardiovasc Med. 2021 Aug 11;8:695547. doi: 10.3389/fcvm.2021.695547. eCollection 2021.
4
Olive Leaf Extract (OLE) impaired vasopressin-induced aquaporin-2 trafficking through the activation of the calcium-sensing receptor.橄榄叶提取物 (OLE) 通过激活钙敏感受体损害了血管加压素诱导的水通道蛋白-2 转运。
Sci Rep. 2021 Feb 25;11(1):4537. doi: 10.1038/s41598-021-83850-5.
5
Fluid Redistribution in Sleep Apnea: Therapeutic Implications in Edematous States.睡眠呼吸暂停中的液体再分布:对水肿状态的治疗意义
Front Med (Lausanne). 2018 Jan 22;4:256. doi: 10.3389/fmed.2017.00256. eCollection 2017.
6
Treatment of Disorders of Sodium Balance in Chronic Kidney Disease.慢性肾脏病钠平衡紊乱的治疗
Adv Chronic Kidney Dis. 2017 Sep;24(5):332-341. doi: 10.1053/j.ackd.2017.07.003.
7
Alpha-2A Adrenoceptor Agonist Guanfacine Restores Diuretic Efficiency in Experimental Cirrhotic Ascites: Comparison with Clonidine.α-2A肾上腺素能受体激动剂胍法辛可恢复实验性肝硬化腹水的利尿效率:与可乐定的比较。
PLoS One. 2016 Jul 6;11(7):e0158486. doi: 10.1371/journal.pone.0158486. eCollection 2016.
8
Prognostic performance of clinical indices and model scorings for acute-on-chronic liver failure: A study of 164 patients.慢性肝衰竭急性发作的临床指标及模型评分的预后性能:一项对164例患者的研究。
Exp Ther Med. 2016 Apr;11(4):1348-1354. doi: 10.3892/etm.2016.3037. Epub 2016 Jan 29.
9
Clinical Use of Diuretics in Heart Failure, Cirrhosis, and Nephrotic Syndrome.利尿剂在心力衰竭、肝硬化和肾病综合征中的临床应用。
Int J Nephrol. 2015;2015:975934. doi: 10.1155/2015/975934. Epub 2015 Jul 29.
10
A novel vasopressin-induced transcript promotes MAP kinase activation and ENaC downregulation.一种新型血管加压素诱导转录本促进丝裂原活化蛋白激酶激活和上皮钠通道下调。
EMBO J. 2002 Oct 1;21(19):5109-17. doi: 10.1093/emboj/cdf509.